menu
    • menu
    [{"orgOrder":0,"company":"Advanced Accelerator Applications","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lutetium-177 Vipivotide Tetraxetan","moa":"DNA | Glutamate carboxypeptidase II","graph1":"Oncology","graph2":"Phase II","graph3":"Advanced Accelerator Applications","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advanced Accelerator Applications \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Advanced Accelerator Applications \/ Undisclosed"},{"orgOrder":0,"company":"Advanced Accelerator Applications","sponsor":"Isotope Technologies Munich","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compound","year":"2020","type":"Agreement","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Advanced Accelerator Applications","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Advanced Accelerator Applications \/ Endocyte","highestDevelopmentStatusID":"15","companyTruncated":"Advanced Accelerator Applications \/ Endocyte"},{"orgOrder":0,"company":"Advanced Accelerator Applications","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Advanced Accelerator Applications","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Advanced Accelerator Applications \/ Advanced Accelerator Applications","highestDevelopmentStatusID":"15","companyTruncated":"Advanced Accelerator Applications \/ Advanced Accelerator Applications"},{"orgOrder":0,"company":"Advanced Accelerator Applications","sponsor":"ABX Advanced Biochemical Compounds","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compound","year":"2022","type":"Agreement","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Advanced Accelerator Applications","amount2":0.17000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Injection","sponsorNew":"Advanced Accelerator Applications \/ Endocyte","highestDevelopmentStatusID":"15","companyTruncated":"Advanced Accelerator Applications \/ Endocyte"},{"orgOrder":0,"company":"Advanced Accelerator Applications","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"177-Lu Vipivotide Tetraxetan","moa":"Ionising radiation","graph1":"Oncology","graph2":"Approved FDF","graph3":"Advanced Accelerator Applications","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Advanced Accelerator Applications \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Advanced Accelerator Applications \/ Undisclosed"},{"orgOrder":0,"company":"Advanced Accelerator Applications","sponsor":"Advanced Accelerator Applications","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"177-Lu Dotatate Lutenium","moa":"SST2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Advanced Accelerator Applications","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Advanced Accelerator Applications \/ Advanced Accelerator Applications","highestDevelopmentStatusID":"8","companyTruncated":"Advanced Accelerator Applications \/ Advanced Accelerator Applications"},{"orgOrder":0,"company":"Advanced Accelerator Applications","sponsor":"Advanced Accelerator Applications","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"177-Lu DOTA-TATE","moa":"SSTR2","graph1":"Oncology","graph2":"Phase I","graph3":"Advanced Accelerator Applications","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advanced Accelerator Applications \/ Advanced Accelerator Applications","highestDevelopmentStatusID":"6","companyTruncated":"Advanced Accelerator Applications \/ Advanced Accelerator Applications"},{"orgOrder":0,"company":"Advanced Accelerator Applications","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"177-Lu Oxodotreotide","moa":"SSTR2","graph1":"Oncology","graph2":"Phase II","graph3":"Advanced Accelerator Applications","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advanced Accelerator Applications \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Advanced Accelerator Applications \/ Undisclosed"},{"orgOrder":0,"company":"Advanced Accelerator Applications","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"L-Arginine","moa":"Vasopressin receptor","graph1":"Oncology","graph2":"Phase IV","graph3":"Advanced Accelerator Applications","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advanced Accelerator Applications \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Advanced Accelerator Applications \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Advanced Accelerator Applications

    Menu

    Advanced Accelerator Applications

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Advanced Accelerator Applications

                            France arrow
                            PREP
                            Not Confirmed

                            Advanced Accelerator Applications

                            France arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu Vipivotide Tetraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MHRA Grants Marketing Authorisation for Novartis’ Radioligand Therapy Pluvicto® (Lutetium (¹⁷⁷lu) Vipi...

                            Details : Pluvicto® (lutetium (177Lu) vipivotide tetraxetan) is indicated for the treatment of adult patients with PSMA-positive mCRPC who have been treated with AR pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.

                            Product Name : Pluvicto

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            August 11, 2022

                            Lead Product(s) : 177-Lu Vipivotide Tetraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Advanced Accelerator Applications

                            France arrow
                            PREP
                            Not Confirmed

                            Advanced Accelerator Applications

                            France arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu Vipivotide Tetraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : ABX Advanced Biochemical Compounds

                            Deal Size : $172.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Otsuka Subsidiary to Receive Payment and Royalties from Approval in U.S. of - Out-licensed by ABX in Germany, ...

                            Details : Advanced Accelerator Applications (AAA) and Endocyte, Inc., both Novartis companies, successfully completed full-scale development of Pluvicto and also received Breakthrough Therapy designation from the U.S. FDA last year.

                            Product Name : Pluvicto

                            Product Type : Radiolabeled Compound

                            Upfront Cash : $12.0 million

                            March 29, 2022

                            Lead Product(s) : 177-Lu Vipivotide Tetraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : ABX Advanced Biochemical Compounds

                            Deal Size : $172.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Advanced Accelerator Applications

                            France arrow
                            PREP
                            Not Confirmed

                            Advanced Accelerator Applications

                            France arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu Vipivotide Tetraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Novartis Pharmaceuticals Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Novartis Pluvicto™ Approved by FDA as First Targeted Radioligand Therapy for Treatment of Progressive, PSMA-...

                            Details : FDA approval was based on VISION trial, where patients with pre-treated PSMA-positive mCRPC who received Pluvicto plus standard of care had a statistically significant reduction in risk of death1; both alternate primary endpoints of OS and radiographic P...

                            Product Name : Pluvicto

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            March 23, 2022

                            Lead Product(s) : 177-Lu Vipivotide Tetraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Novartis Pharmaceuticals Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Advanced Accelerator Applications

                            France arrow
                            PREP
                            Not Confirmed

                            Advanced Accelerator Applications

                            France arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu Dotatate Lutenium

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : University Hospital, Bordeaux

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant ...

                            Details : 177-Lu Dotatate Lutenium is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neuroendocrine Tumors.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            April 08, 2021

                            Lead Product(s) : 177-Lu Dotatate Lutenium

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : University Hospital, Bordeaux

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Advanced Accelerator Applications

                            France arrow
                            PREP
                            Not Confirmed

                            Advanced Accelerator Applications

                            France arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            177Lu-PSMA-617 Managed Access Program for mCRPC Patients

                            Details : 177Lu-PSMA-617 is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Prostatic Neoplasms, Castration-Resistant.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 01, 2021

                            Lead Product(s) : Lutetium-177 Vipivotide Tetraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Advanced Accelerator Applications

                            France arrow
                            PREP
                            Not Confirmed

                            Advanced Accelerator Applications

                            France arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu Oxodotreotide

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

                            Details : 177-Lu Oxodotreotide is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Gastro-enteropancreatic Neuroendocrine Tumor.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            January 15, 2021

                            Lead Product(s) : 177-Lu Oxodotreotide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Advanced Accelerator Applications

                            France arrow
                            PREP
                            Not Confirmed

                            Advanced Accelerator Applications

                            France arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : L-Arginine

                            Therapeutic Area : Oncology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (G...

                            Details : Arginine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Gastro-enteropancreatic Neuroendocrine Tumor.

                            Product Name : Undisclosed

                            Product Type : Amino Acid

                            Upfront Cash : Inapplicable

                            August 24, 2020

                            Lead Product(s) : L-Arginine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Advanced Accelerator Applications

                            France arrow
                            PREP
                            Not Confirmed

                            Advanced Accelerator Applications

                            France arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu DOTA-TATE

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Vastra Gotaland Region

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours

                            Details : 177-Lu DOTA-TATE is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neuroendocrine Tumors.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            May 05, 2020

                            Lead Product(s) : 177-Lu DOTA-TATE

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Vastra Gotaland Region

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Advanced Accelerator Applications

                            France arrow
                            PREP
                            Not Confirmed

                            Advanced Accelerator Applications

                            France arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu Vipivotide Tetraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Isotope Technologies Munich

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            ITM expands PSMA-617 supply agreement for no-carrier-added Lutetium-177

                            Details : ITM will provide Endocyte with supply of n.c.a 177Lu for its investigational 177Lu-PSMA-617 radioligand therapy for patients with metastatic castration-resistant prostate cancer.

                            Product Name : Pluvicto

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            March 02, 2020

                            Lead Product(s) : 177-Lu Vipivotide Tetraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Isotope Technologies Munich

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Advanced Accelerator Applications

                            France arrow
                            PREP
                            Not Confirmed

                            Advanced Accelerator Applications

                            France arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu Dotatate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Recipient : King's College Hospital NHS Trust

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy

                            Details : 177-Lu Dotatate is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoid Heart Disease.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            July 31, 2019

                            Lead Product(s) : 177-Lu Dotatate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Recipient : King's College Hospital NHS Trust

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth